NEW YORK – Qiagen said on Tuesday after the close of the market that it is collaborating with Mirati Therapeutics to develop a tissue-based companion diagnostic test to identify cancer patients who may benefit from adagrasib, Mirati's investigational oral small molecule inhibitor of KRAS G12C.
The agreement initially focuses on a CDx test for non-small cell lung cancer and allows for further development of tests for other Mirati oncology programs, Qiagen said.
The planned test would be part of Qiagen's Therascreen KRAS testing portfolio based on real-time qualitative PCR for the Qiagen Rotor-Gene Q MDx instrument. Qiagen and Mirati also previously partnered to develop a CDx test to detect RNA biomarkers produced by exon 14 skipping mutations in the MET gene to identify NSCLC patients who might benefit from Mirati's glesatinib.
Earlier this year, Mirati struck a CDx development deal with Resolution Bioscience, which is using its sequencing-based liquid biopsy technology to help find NSCLC patients who may benefit from adagrasib.